Meeting
2020 Gastrointestinal Cancers Symposium
An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).
Authors
Akihito Kawazoe
National Cancer Center Hopital East, Kashiwa, Japan
Akihito Kawazoe , Shota Fukuoka , Yoshiaki Nakamura , Yasutoshi Kuboki , Yuichi Mikamoto , Hikari Shima , Noriko Fujishiro , Tsukiko Higuchi , Masashi Wakabayashi , Shogo Nomura , Akihiro Sato , Kohei Shitara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03609359
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 374)
Abstract #
374
Poster Bd #
E7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2022 ASCO Annual Meeting
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2021 ASCO Annual Meeting
KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).
First Author: Chung-Han Lee